ACTRN12620001019998已完成1 期
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor Antagonist in healthy adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- All
入选标准
- •Screening laboratory evaluations and 12-lead ECG evaluations must be without clinically
- •significant abnormalities as assessed by the investigator
- •- Must, in the opinion of the investigator, be in good health based upon medical history and
- •physical examination, including vital signs
排除标准
- •- Pregnant or Breastfeeding
- •- Have received any study drug within 30 days prior to study dosing
- •- Have poor venous access that limits phlebotomy
研究者
相似试验
招募中
1 期
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620001261909Ascil Australia Pty LTD16
已完成
1 期
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620000108910Ascil Australia Pty Ltd8
招募中
1 期
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38
进行中（未招募）
不适用
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32